Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, IDT Ally to Offer Oligo Synthesis Services to Pharmas

NEW YORK (GenomeWeb News) - Agilent Technologies and Integrated DNA Technologies will jointly offer oligo synthesis and other products and services to create a "complete development pathway" for drug developers, the companies said yesterday.
 
The companies said they will provide reciprocal referrals for synthetic oligonucleotides and will offer chemical and analytical services designed to help customers reduce time and costs associated with moving from research to clinical development.
 
Under the agreement, IDT will produce small-scale and mid-scale products for use in research and drug screening, while Agilent's Nucleic Acid Solutions division will contribute large-scale quantities of oligos to be used as active pharmaceutical ingredients in clinical trials and drug manufacturing.
 
IDT's COO, Trey Martin, said the agreement allows the companies to offer "a bench-to-bedside oligonucleotide manufacturing package," that includes "harmonized manufacturing methods from basic research scales through API manufacturing."

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.